Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$254.28 USD

254.28
516,638

+5.58 (2.24%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $254.09 -0.19 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Jazz Pharmaceuticals and Boston Beer Company have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Jazz Pharmaceuticals and Boston Beer Company are part of the Zacks Bull and Bear of the Day article.

Bryan Hayes headshot

Bull of the Day: Jazz Pharmaceuticals (JAZZ)

by Bryan Hayes

The company boasts a strong drug portfolio with a primary focus in the areas of neuroscience and oncology.

Benjamin Rains headshot

Finding Great Momentum Stocks to Buy in March During the Selloff

by Benjamin Rains

Today we explore a screen that helps investors find surging stocks trading near fresh highs in early March amid the broader stock market selloff.

Urmimala Biswas headshot

4 Discounted PEG Stocks Offering the Best Returns to Value Investors

by Urmimala Biswas

Here we present four discounted PEG stocks that qualify our screening criteria, TAP, BMRN, DVN and JAZZ.

Zacks Equity Research

Corcept Shares Rise More Than 55% in 6 Months: Here's Why

by Zacks Equity Research

CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well.

Zacks Equity Research

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

by Zacks Equity Research

Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.

Zacks Equity Research

Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More

by Zacks Equity Research

CMRX and JAZZ are in the spotlight this week following an acquisition agreement.

Zacks Equity Research

AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

by Zacks Equity Research

Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.

Zacks Equity Research

Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio

by Zacks Equity Research

JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.

Nilanjan Banerjee headshot

Beat Market Volatility With 4 Low-Beta Stocks: PGR, PSO, TXO & JAZZ

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. PGR, PSO, TXO & JAZZ are well-poised to gain.